RESUMO
BACKGROUND: Zika virus (ZIKV) infection is a global health problem, and its complications, including congenital Zika syndrome and Guillain-Barré syndrome, constitute a continued threat to humans. Unfortunately, effective therapeutics against ZIKV infection are not available thus far. METHODS: We screened the compounds collection consisting of 1789 FDA-approved drugs by a computational docking method to obtain anti-ZIKV candidate compounds targeting ZIKV RNA-dependent RNA polymerase (RdRp). SPR (BIAcore) assay was employed to demonstrate the candidate compounds' direct binding to ZIKV RdRp, and polymerase activity assay was used to determine the inhibitory effect on ZIKV RdRp-catalyzed RNA synthesis. The antiviral effects on ZIKV in vitro and in vivo were detected in infected cultured cells and in Ifnar1-/- mice infected by ZIKV virus using plaque assay, western blotting, tissue immunofluorescence, and immunohistochemistry. RESULTS: Here, we report that a first-in-class macrocyclic antibiotic, which has been clinically used to treat Clostridium difficile infection, fidaxomicin, potently inhibits ZIKV replication in vitro and in vivo. Our data showed that fidaxomicin was effective against African and Asian lineage ZIKV in a wide variety of cell lines of various tissue origins, and prominently suppressed ZIKV infection and significantly improved survival of infected mice. In addition, fidaxomicin treatment reduced the virus load in the brains and testes, and alleviated ZIKV-associated pathological damages, such as paralysis, hunching, and neuronal necrosis in the cerebra. Furthermore, our mechanistic study showed that fidaxomicin directly bound ZIKV NS5 protein and inhibited the RNA synthesis-catalyzing activity of ZIKV RdRp. CONCLUSIONS: Our data suggest that fidaxomicin may represent an effective anti-ZIKV agent. In the light that fidaxomicin is already a clinically used drug, there might be a promising prospect in the development of fidaxomicin to be an antiviral therapeutic.
Assuntos
Fidaxomicina/uso terapêutico , RNA Polimerase Dependente de RNA/uso terapêutico , Infecção por Zika virus/tratamento farmacológico , Animais , Linhagem Celular Tumoral , Chlorocebus aethiops , Feminino , Fidaxomicina/farmacologia , Células Endoteliais da Veia Umbilical Humana , Humanos , Masculino , Camundongos , RNA Polimerase Dependente de RNA/farmacologia , Células Vero , Infecção por Zika virus/patologiaRESUMO
BACKGROUND: Hepatitis C is an inflammatory condition of the liver caused by the hepatitis C virus, exhibiting acute and chronic manifestations with severity ranging from mild to severe and lifelong illnesses leading to liver cirrhosis and cancer. According to the World Health Organization's global estimates, a population of about 58 million have chronic hepatitis C virus infection, with around 1.5 million new infections occurring every year. OBJECTIVE: The present study aimed to identify novel molecules targeting the Hepatitis C viral RNA Dependent RNA polymerases, which play a crucial role in genome replication, mRNA synthesis, etc. Methods: Structure-based virtual screening of chemical libraries of small molecules was done using AutoDock/Vina. The top-ranking pose for every ligand was complexed with the protein and used for further protein-ligand interaction analysis using the Protein-ligand interaction Profiler. Molecules from virtual screening were further assessed using the pkCSM web server. The proteinligand interactions were further subjected to molecular dynamics simulation studies to establish dynamic stability. RESULTS: Molecular docking-based virtual screening of the database of small molecules, followed by screening based on pharmacokinetic and toxicity parameters, yielded eight probable RNA Dependent RNA polymerase inhibitors. The docking scores for the proposed candidates ranged from - 8.04 to -9.10 kcal/mol. The potential stability of the ligands bound to the target protein was demonstrated by molecular dynamics simulation studies. CONCLUSION: Data from exhaustive computational studies proposed eight molecules as potential anti-viral candidates, targeting Hepatitis C viral RNA Dependent RNA polymerases, which can be further evaluated for their biological potential.
Assuntos
Hepatite C Crônica , Hepatite C , Humanos , Hepacivirus , Simulação de Acoplamento Molecular , RNA Polimerase Dependente de RNA/química , RNA Polimerase Dependente de RNA/uso terapêutico , Ligantes , Hepatite C/tratamento farmacológico , Simulação de Dinâmica Molecular , RNA Viral , RNA Polimerases Dirigidas por DNA/uso terapêutico , Antivirais/farmacologia , Antivirais/químicaRESUMO
Unimolecular micelles (UIMs) exhibit promising potential in the precise diagnosis and accurate treatment of tumor tissues, a pressing problem in the field of medical treatment, because of their perfect stability in the complex and variable microenvironment. In this study, porphyrin-based four-armed star-shaped block polymers with narrow molar mass dispersity (D = 1.34) were facilely prepared by photocontrolled bromine-iodine transformation reversible-deactivation radical polymerization (BIT-RDRP). A photothermal conversion dye, ketocyanine, was covalently linked onto the PEG and then introduced into the polymers through a "grafting onto" strategy to obtain polymeric nanomaterial, THPP-4PMMA-b-4P(PEGMA-co-APMA)@NIR-800, with dual PTT/PDT function. The resulting polymers could form monodispersed UIMs in the water below critical aggregation concentration, meanwhile maintaining the capacities of singlet oxygen release and photothermal conversion. Importantly, the UIMs displayed excellent biocompatibility while exerting superior PTT and/or PDT therapeutic effects under the irradiation of specific wavelengths of light, according to in vitro cellular experiments, which is expected to become a new hot spot for cancer therapy and anti-tumor research. Overall, stable and powerful UIMs with dual PTT/PDT function is provided, which are expected to be competitive candidates in cancer therapy.
Assuntos
Neoplasias , Fotoquimioterapia , Humanos , Fotoquimioterapia/métodos , Fármacos Fotossensibilizantes , Micelas , Polímeros/uso terapêutico , Bromo/uso terapêutico , Polimerização , Neoplasias/tratamento farmacológico , RNA Polimerase Dependente de RNA/uso terapêutico , Microambiente TumoralRESUMO
'Naked' nucleic acid vaccines are potentially useful candidates for the treatment of patients with cancer, but their clinical efficacy has yet to be demonstrated. We sought to enhance the immunogenicity of a nucleic acid vaccine by making it 'self-replicating'. We accomplished this by using a gene encoding an RNA replicase polyprotein derived from the Semliki forest virus, in combination with a model antigen. A single intramuscular injection of a self-replicating RNA immunogen elicited antigen-specific antibody and CD8+ T-cell responses at doses as low as 0.1 microg. Pre-immunization with a self-replicating RNA vector protected mice from tumor challenge, and therapeutic immunization prolonged the survival of mice with established tumors. The self-replicating RNA vectors did not mediate the production of substantially more model antigen than a conventional DNA vaccine did in vitro. However, the enhanced efficacy in vivo correlated with a caspase-dependent apoptotic death in transfected cells. This death facilitated the uptake of apoptotic cells by dendritic cells, providing a potential mechanism for enhanced immunogenicity. Naked, non-infectious, self-replicating RNA may be an excellent candidate for the development of new cancer vaccines.
Assuntos
Linfócitos B/imunologia , Linfócitos T CD8-Positivos/imunologia , Vacinas Anticâncer/uso terapêutico , Neoplasias do Colo/prevenção & controle , RNA Polimerase Dependente de RNA/genética , RNA Polimerase Dependente de RNA/uso terapêutico , Animais , Formação de Anticorpos , Apoptose , Neoplasias do Colo/imunologia , Células Dendríticas/imunologia , Elementos Facilitadores Genéticos , Injeções Intramusculares , Camundongos , Camundongos Endogâmicos BALB C , Plasmídeos , Regiões Promotoras Genéticas , RNA Polimerase Dependente de RNA/biossíntese , Proteínas Recombinantes/biossíntese , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Vírus da Floresta de Semliki/enzimologia , Vírus da Floresta de Semliki/genética , Transfecção , Células Tumorais CultivadasRESUMO
Hepatitis C virus (HCV) infection is the leading cause of chronic liver diseases worldwide. There is no vaccine to prevent HCV infection. Current standard of care (SOC) for hepatitis C is pegylated interferon-α (pegIFN-α) in combination with ribavirin (RBV). However, the efficacy of pegIFN-α and RBV combination therapy is less than 50% for genotype 1 HCV, which is the dominant virus in human. Additionally, IFN and RBV are highly toxic, causing severe side effects. Therefore, it is urgent to develop safer and more efficacious anti-HCV drugs. Over the last decade, a number of HCV-specific inhibitors have been discovered with many of them reached to late stages of clinical trials. Recently, 2 HCV NS3 protease inhibitors, telaprevir and boceprevir, have been approved by the Unite States Food and Drug Administration (FDA). This opens up a new era for anti-HCV therapy. Several new classes of antiviral drugs targeting HCV NS3 protease, NS5A and NS5B RNA-dependence RNA polymerase (RdRp) are currently at various stages of preclinical and clinical studies. Upon approval of more NS3 protease, NS5A and NS5B polymerase inhibitors, future clinical studies will lead to optimal combination therapies which will have desirable parameters such as IFN-free, higher efficacy, safe, one daily dose and short duration.